Global Cancer Biological Therapy

Cancer Biological Therapy Comprehensive Study by Type (Monoclonal Antibodies, Vaccines, Cancer Growth Blockers, Blood Cell Growth Factors), Application (Hospitals, Diagnostic Laboratories, Research & Academic Laboratories, Pharmaceutical & Biotechnology Companies), Cancer (Brain, Blood, Lungs, Breast, Bladder, Prostate, Others) Players and Region - Global Market Outlook to 2028

Cancer Biological Therapy Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
As with the growing incidence of cancer across the globe is increasing day by day. Many researchers are approaching various treatments to tackle this issue. There, biological therapy is playing a major role. These biological agents are formed a few targeting therapies where only cancer cells are affected by the drugs. It is majorly suits for the invasive therapy. Almost 70% of the biological therapy is based on the body’s immune system and other is based on cell signaling. According to that the immune system plays an essential role in these biological therapies and decides the success rate of the treatment.This growth is primarily driven by Increase in incidence of cancer across the globe. There are near about ~33 million people are fighting with cancer across the globe. According to a few syndicated research, there are 70 % chances of increasing the number of cancer cases across the globe. Across the globe, people are investing in various new research to treat cancer..

AttributesDetails
Study Period2018-2028
Base Year2022
Forecast Period2023-2028
Volume UnitN
Value UnitUSD (Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


The Diseases & Therapeutic Areas sector in the region has been increasing at a sustainable rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as ELI Lilly (United States), Sanofi (France), Merck (United States), Bayer (Germany), Roche (Switzerland), Novartis International (Switzerland), Pfizer (United States), Bristol-Myers Squibb (United States), Seattle Genetics (United States) and Amgen (United States), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
In December 2021, Sanofi acquired Amunix immuno-oncology pipeline with next-generation Conditionally Activated Biologics. It includes Amunix's proprietary XTEN technology, which extends the half-life of therapeutic proteins, and its Pro-XTEN platform, which enables the development of conditionally activated biologics that are activated only in the tumor microenvironment. This strategical acquisition aimed to accelerate and expand its contributions to innovative medicines for oncology patients.
In December 2021, Eli Lilly formed strategic collaboration with Foghorn Therapeutics Inc. (Foghorn) to discover and develop potential new medicines for cancer by applying Foghorn's proprietary Gene Traffic Control platform. This collaboration is further estimated to leverage Foghorn's proprietary Gene Traffic Control platform to identify novel targets for Lilly's oncology research programs.The companies operating in these industries are focusing more on efficient growth, improvement of operational efficiency and productivity, achieving high safety standards, and focus on maintaining sustainable development. The players are focusing towards securing the leading position in this industry. They are continuously looking for the opportunity to reinforce their competitive advantage. To meet a high market share, and developing socially responsible business companies are identifying various strategic pillars such as mergers & acquisitions, new product launch, product enhancement, and others.

Influencing Trend:
Advancement in Research and Development Sector on the Molecular Basis of Cancer Which Include Articles with Translational Relevance to Diagnosis and Therapy

Market Growth Drivers:
Increase in incidence of cancer across the globe. There are near about ~33 million people are fighting with cancer across the globe. According to a few syndicated research, there are 70 % chances of increasing the number of cancer cases across the globe. Across the globe, people are investing in various new research to treat cancer.

Challenges:
Lack Of Appropriate Models and Hypotheses and To Translate Information for the Clinicians and the Benefit of Their Patients

Restraints:
Huge Expenditure Required On the Drug Development and Rising Concern towards the Side Effect of the Drugs

Opportunities:
Improvement of Health Facility in Asia Pacific Regions and High Adoption of Cancer Therapy in North America Regions

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mainly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the market's growth. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Data Sources of Cancer Biological Therapy Market Study

Primary Collection: InMail, LinkedIn Groups, Survey Monkey, Google, and Other professional Forums are some of the mediums utilized to gather primary data through key industry participants and appointees, subject-matter experts, C-level executives of Cancer Biological Therapy Industry, among others including independent industry consultants, experts, to obtain and verify critical qualitative commentary and opinion and quantitative statistics, to assess future market prospects.

The primary interviews and data collected as per the below protocols:
• By Designation: C-Level, D-Level, Others
• By Company Type: Tier 1, Tier 2, Tier 3

Secondary Data Sources such as Annual reports, Press releases, Analyst meetings, Conference calls, Investor presentations, Management statements, and SEC filings of Cancer Biological Therapy players along with Regulatory Sites, Association, World bank, etc were used as sources secondary set of data.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Cancer Biological Therapy Study Sheds Light on
— The Cancer Biological Therapy Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Cancer Biological Therapy industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Cancer Biological Therapy industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Monoclonal Antibodies
  • Vaccines
  • Cancer Growth Blockers
  • Blood Cell Growth Factors
By Application
  • Hospitals
  • Diagnostic Laboratories
  • Research & Academic Laboratories
  • Pharmaceutical & Biotechnology Companies
By Cancer
  • Brain
  • Blood
  • Lungs
  • Breast
  • Bladder
  • Prostate
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in incidence of cancer across the globe. There are near about ~33 million people are fighting with cancer across the globe. According to a few syndicated research, there are 70 % chances of increasing the number of cancer cases across the globe. Across the globe, people are investing in various new research to treat cancer.
    • 3.3. Market Challenges
      • 3.3.1. Lack Of Appropriate Models and Hypotheses and To Translate Information for the Clinicians and the Benefit of Their Patients
    • 3.4. Market Trends
      • 3.4.1. Advancement in Research and Development Sector on the Molecular Basis of Cancer Which Include Articles with Translational Relevance to Diagnosis and Therapy
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Cancer Biological Therapy, by Type, Application, Cancer and Region (value and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Cancer Biological Therapy (Value)
      • 5.2.1. Global Cancer Biological Therapy by: Type (Value)
        • 5.2.1.1. Monoclonal Antibodies
        • 5.2.1.2. Vaccines
        • 5.2.1.3. Cancer Growth Blockers
        • 5.2.1.4. Blood Cell Growth Factors
      • 5.2.2. Global Cancer Biological Therapy by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Diagnostic Laboratories
        • 5.2.2.3. Research & Academic Laboratories
        • 5.2.2.4. Pharmaceutical & Biotechnology Companies
      • 5.2.3. Global Cancer Biological Therapy by: Cancer (Value)
        • 5.2.3.1. Brain
        • 5.2.3.2. Blood
        • 5.2.3.3. Lungs
        • 5.2.3.4. Breast
        • 5.2.3.5. Bladder
        • 5.2.3.6. Prostate
        • 5.2.3.7. Others
      • 5.2.4. Global Cancer Biological Therapy Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Cancer Biological Therapy (Price)
      • 5.3.1. Global Cancer Biological Therapy by: Type (Price)
  • 6. Cancer Biological Therapy: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. ELI Lilly (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Sanofi (France)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Merck (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bayer (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Roche (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Novartis International (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Pfizer (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Bristol-Myers Squibb (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Seattle Genetics (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Amgen (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Cancer Biological Therapy Sale, by Type, Application, Cancer and Region (value and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Cancer Biological Therapy (Value)
      • 7.2.1. Global Cancer Biological Therapy by: Type (Value)
        • 7.2.1.1. Monoclonal Antibodies
        • 7.2.1.2. Vaccines
        • 7.2.1.3. Cancer Growth Blockers
        • 7.2.1.4. Blood Cell Growth Factors
      • 7.2.2. Global Cancer Biological Therapy by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Diagnostic Laboratories
        • 7.2.2.3. Research & Academic Laboratories
        • 7.2.2.4. Pharmaceutical & Biotechnology Companies
      • 7.2.3. Global Cancer Biological Therapy by: Cancer (Value)
        • 7.2.3.1. Brain
        • 7.2.3.2. Blood
        • 7.2.3.3. Lungs
        • 7.2.3.4. Breast
        • 7.2.3.5. Bladder
        • 7.2.3.6. Prostate
        • 7.2.3.7. Others
      • 7.2.4. Global Cancer Biological Therapy Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Cancer Biological Therapy (Price)
      • 7.3.1. Global Cancer Biological Therapy by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Cancer Biological Therapy: by Type(USD Million)
  • Table 2. Cancer Biological Therapy Monoclonal Antibodies , by Region USD Million (2017-2022)
  • Table 3. Cancer Biological Therapy Vaccines , by Region USD Million (2017-2022)
  • Table 4. Cancer Biological Therapy Cancer Growth Blockers , by Region USD Million (2017-2022)
  • Table 5. Cancer Biological Therapy Blood Cell Growth Factors , by Region USD Million (2017-2022)
  • Table 6. Cancer Biological Therapy: by Application(USD Million)
  • Table 7. Cancer Biological Therapy Hospitals , by Region USD Million (2017-2022)
  • Table 8. Cancer Biological Therapy Diagnostic Laboratories , by Region USD Million (2017-2022)
  • Table 9. Cancer Biological Therapy Research & Academic Laboratories , by Region USD Million (2017-2022)
  • Table 10. Cancer Biological Therapy Pharmaceutical & Biotechnology Companies , by Region USD Million (2017-2022)
  • Table 11. Cancer Biological Therapy: by Cancer(USD Million)
  • Table 12. Cancer Biological Therapy Brain , by Region USD Million (2017-2022)
  • Table 13. Cancer Biological Therapy Blood , by Region USD Million (2017-2022)
  • Table 14. Cancer Biological Therapy Lungs , by Region USD Million (2017-2022)
  • Table 15. Cancer Biological Therapy Breast , by Region USD Million (2017-2022)
  • Table 16. Cancer Biological Therapy Bladder , by Region USD Million (2017-2022)
  • Table 17. Cancer Biological Therapy Prostate , by Region USD Million (2017-2022)
  • Table 18. Cancer Biological Therapy Others , by Region USD Million (2017-2022)
  • Table 19. South America Cancer Biological Therapy, by Country USD Million (2017-2022)
  • Table 20. South America Cancer Biological Therapy, by Type USD Million (2017-2022)
  • Table 21. South America Cancer Biological Therapy, by Application USD Million (2017-2022)
  • Table 22. South America Cancer Biological Therapy, by Cancer USD Million (2017-2022)
  • Table 23. Brazil Cancer Biological Therapy, by Type USD Million (2017-2022)
  • Table 24. Brazil Cancer Biological Therapy, by Application USD Million (2017-2022)
  • Table 25. Brazil Cancer Biological Therapy, by Cancer USD Million (2017-2022)
  • Table 26. Argentina Cancer Biological Therapy, by Type USD Million (2017-2022)
  • Table 27. Argentina Cancer Biological Therapy, by Application USD Million (2017-2022)
  • Table 28. Argentina Cancer Biological Therapy, by Cancer USD Million (2017-2022)
  • Table 29. Rest of South America Cancer Biological Therapy, by Type USD Million (2017-2022)
  • Table 30. Rest of South America Cancer Biological Therapy, by Application USD Million (2017-2022)
  • Table 31. Rest of South America Cancer Biological Therapy, by Cancer USD Million (2017-2022)
  • Table 32. Asia Pacific Cancer Biological Therapy, by Country USD Million (2017-2022)
  • Table 33. Asia Pacific Cancer Biological Therapy, by Type USD Million (2017-2022)
  • Table 34. Asia Pacific Cancer Biological Therapy, by Application USD Million (2017-2022)
  • Table 35. Asia Pacific Cancer Biological Therapy, by Cancer USD Million (2017-2022)
  • Table 36. China Cancer Biological Therapy, by Type USD Million (2017-2022)
  • Table 37. China Cancer Biological Therapy, by Application USD Million (2017-2022)
  • Table 38. China Cancer Biological Therapy, by Cancer USD Million (2017-2022)
  • Table 39. Japan Cancer Biological Therapy, by Type USD Million (2017-2022)
  • Table 40. Japan Cancer Biological Therapy, by Application USD Million (2017-2022)
  • Table 41. Japan Cancer Biological Therapy, by Cancer USD Million (2017-2022)
  • Table 42. India Cancer Biological Therapy, by Type USD Million (2017-2022)
  • Table 43. India Cancer Biological Therapy, by Application USD Million (2017-2022)
  • Table 44. India Cancer Biological Therapy, by Cancer USD Million (2017-2022)
  • Table 45. South Korea Cancer Biological Therapy, by Type USD Million (2017-2022)
  • Table 46. South Korea Cancer Biological Therapy, by Application USD Million (2017-2022)
  • Table 47. South Korea Cancer Biological Therapy, by Cancer USD Million (2017-2022)
  • Table 48. Taiwan Cancer Biological Therapy, by Type USD Million (2017-2022)
  • Table 49. Taiwan Cancer Biological Therapy, by Application USD Million (2017-2022)
  • Table 50. Taiwan Cancer Biological Therapy, by Cancer USD Million (2017-2022)
  • Table 51. Australia Cancer Biological Therapy, by Type USD Million (2017-2022)
  • Table 52. Australia Cancer Biological Therapy, by Application USD Million (2017-2022)
  • Table 53. Australia Cancer Biological Therapy, by Cancer USD Million (2017-2022)
  • Table 54. Rest of Asia-Pacific Cancer Biological Therapy, by Type USD Million (2017-2022)
  • Table 55. Rest of Asia-Pacific Cancer Biological Therapy, by Application USD Million (2017-2022)
  • Table 56. Rest of Asia-Pacific Cancer Biological Therapy, by Cancer USD Million (2017-2022)
  • Table 57. Europe Cancer Biological Therapy, by Country USD Million (2017-2022)
  • Table 58. Europe Cancer Biological Therapy, by Type USD Million (2017-2022)
  • Table 59. Europe Cancer Biological Therapy, by Application USD Million (2017-2022)
  • Table 60. Europe Cancer Biological Therapy, by Cancer USD Million (2017-2022)
  • Table 61. Germany Cancer Biological Therapy, by Type USD Million (2017-2022)
  • Table 62. Germany Cancer Biological Therapy, by Application USD Million (2017-2022)
  • Table 63. Germany Cancer Biological Therapy, by Cancer USD Million (2017-2022)
  • Table 64. France Cancer Biological Therapy, by Type USD Million (2017-2022)
  • Table 65. France Cancer Biological Therapy, by Application USD Million (2017-2022)
  • Table 66. France Cancer Biological Therapy, by Cancer USD Million (2017-2022)
  • Table 67. Italy Cancer Biological Therapy, by Type USD Million (2017-2022)
  • Table 68. Italy Cancer Biological Therapy, by Application USD Million (2017-2022)
  • Table 69. Italy Cancer Biological Therapy, by Cancer USD Million (2017-2022)
  • Table 70. United Kingdom Cancer Biological Therapy, by Type USD Million (2017-2022)
  • Table 71. United Kingdom Cancer Biological Therapy, by Application USD Million (2017-2022)
  • Table 72. United Kingdom Cancer Biological Therapy, by Cancer USD Million (2017-2022)
  • Table 73. Netherlands Cancer Biological Therapy, by Type USD Million (2017-2022)
  • Table 74. Netherlands Cancer Biological Therapy, by Application USD Million (2017-2022)
  • Table 75. Netherlands Cancer Biological Therapy, by Cancer USD Million (2017-2022)
  • Table 76. Rest of Europe Cancer Biological Therapy, by Type USD Million (2017-2022)
  • Table 77. Rest of Europe Cancer Biological Therapy, by Application USD Million (2017-2022)
  • Table 78. Rest of Europe Cancer Biological Therapy, by Cancer USD Million (2017-2022)
  • Table 79. MEA Cancer Biological Therapy, by Country USD Million (2017-2022)
  • Table 80. MEA Cancer Biological Therapy, by Type USD Million (2017-2022)
  • Table 81. MEA Cancer Biological Therapy, by Application USD Million (2017-2022)
  • Table 82. MEA Cancer Biological Therapy, by Cancer USD Million (2017-2022)
  • Table 83. Middle East Cancer Biological Therapy, by Type USD Million (2017-2022)
  • Table 84. Middle East Cancer Biological Therapy, by Application USD Million (2017-2022)
  • Table 85. Middle East Cancer Biological Therapy, by Cancer USD Million (2017-2022)
  • Table 86. Africa Cancer Biological Therapy, by Type USD Million (2017-2022)
  • Table 87. Africa Cancer Biological Therapy, by Application USD Million (2017-2022)
  • Table 88. Africa Cancer Biological Therapy, by Cancer USD Million (2017-2022)
  • Table 89. North America Cancer Biological Therapy, by Country USD Million (2017-2022)
  • Table 90. North America Cancer Biological Therapy, by Type USD Million (2017-2022)
  • Table 91. North America Cancer Biological Therapy, by Application USD Million (2017-2022)
  • Table 92. North America Cancer Biological Therapy, by Cancer USD Million (2017-2022)
  • Table 93. United States Cancer Biological Therapy, by Type USD Million (2017-2022)
  • Table 94. United States Cancer Biological Therapy, by Application USD Million (2017-2022)
  • Table 95. United States Cancer Biological Therapy, by Cancer USD Million (2017-2022)
  • Table 96. Canada Cancer Biological Therapy, by Type USD Million (2017-2022)
  • Table 97. Canada Cancer Biological Therapy, by Application USD Million (2017-2022)
  • Table 98. Canada Cancer Biological Therapy, by Cancer USD Million (2017-2022)
  • Table 99. Mexico Cancer Biological Therapy, by Type USD Million (2017-2022)
  • Table 100. Mexico Cancer Biological Therapy, by Application USD Million (2017-2022)
  • Table 101. Mexico Cancer Biological Therapy, by Cancer USD Million (2017-2022)
  • Table 102. Cancer Biological Therapy: by Type(USD/Units)
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Company Basic Information, Sales Area and Its Competitors
  • Table 113. Cancer Biological Therapy: by Type(USD Million)
  • Table 114. Cancer Biological Therapy Monoclonal Antibodies , by Region USD Million (2023-2028)
  • Table 115. Cancer Biological Therapy Vaccines , by Region USD Million (2023-2028)
  • Table 116. Cancer Biological Therapy Cancer Growth Blockers , by Region USD Million (2023-2028)
  • Table 117. Cancer Biological Therapy Blood Cell Growth Factors , by Region USD Million (2023-2028)
  • Table 118. Cancer Biological Therapy: by Application(USD Million)
  • Table 119. Cancer Biological Therapy Hospitals , by Region USD Million (2023-2028)
  • Table 120. Cancer Biological Therapy Diagnostic Laboratories , by Region USD Million (2023-2028)
  • Table 121. Cancer Biological Therapy Research & Academic Laboratories , by Region USD Million (2023-2028)
  • Table 122. Cancer Biological Therapy Pharmaceutical & Biotechnology Companies , by Region USD Million (2023-2028)
  • Table 123. Cancer Biological Therapy: by Cancer(USD Million)
  • Table 124. Cancer Biological Therapy Brain , by Region USD Million (2023-2028)
  • Table 125. Cancer Biological Therapy Blood , by Region USD Million (2023-2028)
  • Table 126. Cancer Biological Therapy Lungs , by Region USD Million (2023-2028)
  • Table 127. Cancer Biological Therapy Breast , by Region USD Million (2023-2028)
  • Table 128. Cancer Biological Therapy Bladder , by Region USD Million (2023-2028)
  • Table 129. Cancer Biological Therapy Prostate , by Region USD Million (2023-2028)
  • Table 130. Cancer Biological Therapy Others , by Region USD Million (2023-2028)
  • Table 131. South America Cancer Biological Therapy, by Country USD Million (2023-2028)
  • Table 132. South America Cancer Biological Therapy, by Type USD Million (2023-2028)
  • Table 133. South America Cancer Biological Therapy, by Application USD Million (2023-2028)
  • Table 134. South America Cancer Biological Therapy, by Cancer USD Million (2023-2028)
  • Table 135. Brazil Cancer Biological Therapy, by Type USD Million (2023-2028)
  • Table 136. Brazil Cancer Biological Therapy, by Application USD Million (2023-2028)
  • Table 137. Brazil Cancer Biological Therapy, by Cancer USD Million (2023-2028)
  • Table 138. Argentina Cancer Biological Therapy, by Type USD Million (2023-2028)
  • Table 139. Argentina Cancer Biological Therapy, by Application USD Million (2023-2028)
  • Table 140. Argentina Cancer Biological Therapy, by Cancer USD Million (2023-2028)
  • Table 141. Rest of South America Cancer Biological Therapy, by Type USD Million (2023-2028)
  • Table 142. Rest of South America Cancer Biological Therapy, by Application USD Million (2023-2028)
  • Table 143. Rest of South America Cancer Biological Therapy, by Cancer USD Million (2023-2028)
  • Table 144. Asia Pacific Cancer Biological Therapy, by Country USD Million (2023-2028)
  • Table 145. Asia Pacific Cancer Biological Therapy, by Type USD Million (2023-2028)
  • Table 146. Asia Pacific Cancer Biological Therapy, by Application USD Million (2023-2028)
  • Table 147. Asia Pacific Cancer Biological Therapy, by Cancer USD Million (2023-2028)
  • Table 148. China Cancer Biological Therapy, by Type USD Million (2023-2028)
  • Table 149. China Cancer Biological Therapy, by Application USD Million (2023-2028)
  • Table 150. China Cancer Biological Therapy, by Cancer USD Million (2023-2028)
  • Table 151. Japan Cancer Biological Therapy, by Type USD Million (2023-2028)
  • Table 152. Japan Cancer Biological Therapy, by Application USD Million (2023-2028)
  • Table 153. Japan Cancer Biological Therapy, by Cancer USD Million (2023-2028)
  • Table 154. India Cancer Biological Therapy, by Type USD Million (2023-2028)
  • Table 155. India Cancer Biological Therapy, by Application USD Million (2023-2028)
  • Table 156. India Cancer Biological Therapy, by Cancer USD Million (2023-2028)
  • Table 157. South Korea Cancer Biological Therapy, by Type USD Million (2023-2028)
  • Table 158. South Korea Cancer Biological Therapy, by Application USD Million (2023-2028)
  • Table 159. South Korea Cancer Biological Therapy, by Cancer USD Million (2023-2028)
  • Table 160. Taiwan Cancer Biological Therapy, by Type USD Million (2023-2028)
  • Table 161. Taiwan Cancer Biological Therapy, by Application USD Million (2023-2028)
  • Table 162. Taiwan Cancer Biological Therapy, by Cancer USD Million (2023-2028)
  • Table 163. Australia Cancer Biological Therapy, by Type USD Million (2023-2028)
  • Table 164. Australia Cancer Biological Therapy, by Application USD Million (2023-2028)
  • Table 165. Australia Cancer Biological Therapy, by Cancer USD Million (2023-2028)
  • Table 166. Rest of Asia-Pacific Cancer Biological Therapy, by Type USD Million (2023-2028)
  • Table 167. Rest of Asia-Pacific Cancer Biological Therapy, by Application USD Million (2023-2028)
  • Table 168. Rest of Asia-Pacific Cancer Biological Therapy, by Cancer USD Million (2023-2028)
  • Table 169. Europe Cancer Biological Therapy, by Country USD Million (2023-2028)
  • Table 170. Europe Cancer Biological Therapy, by Type USD Million (2023-2028)
  • Table 171. Europe Cancer Biological Therapy, by Application USD Million (2023-2028)
  • Table 172. Europe Cancer Biological Therapy, by Cancer USD Million (2023-2028)
  • Table 173. Germany Cancer Biological Therapy, by Type USD Million (2023-2028)
  • Table 174. Germany Cancer Biological Therapy, by Application USD Million (2023-2028)
  • Table 175. Germany Cancer Biological Therapy, by Cancer USD Million (2023-2028)
  • Table 176. France Cancer Biological Therapy, by Type USD Million (2023-2028)
  • Table 177. France Cancer Biological Therapy, by Application USD Million (2023-2028)
  • Table 178. France Cancer Biological Therapy, by Cancer USD Million (2023-2028)
  • Table 179. Italy Cancer Biological Therapy, by Type USD Million (2023-2028)
  • Table 180. Italy Cancer Biological Therapy, by Application USD Million (2023-2028)
  • Table 181. Italy Cancer Biological Therapy, by Cancer USD Million (2023-2028)
  • Table 182. United Kingdom Cancer Biological Therapy, by Type USD Million (2023-2028)
  • Table 183. United Kingdom Cancer Biological Therapy, by Application USD Million (2023-2028)
  • Table 184. United Kingdom Cancer Biological Therapy, by Cancer USD Million (2023-2028)
  • Table 185. Netherlands Cancer Biological Therapy, by Type USD Million (2023-2028)
  • Table 186. Netherlands Cancer Biological Therapy, by Application USD Million (2023-2028)
  • Table 187. Netherlands Cancer Biological Therapy, by Cancer USD Million (2023-2028)
  • Table 188. Rest of Europe Cancer Biological Therapy, by Type USD Million (2023-2028)
  • Table 189. Rest of Europe Cancer Biological Therapy, by Application USD Million (2023-2028)
  • Table 190. Rest of Europe Cancer Biological Therapy, by Cancer USD Million (2023-2028)
  • Table 191. MEA Cancer Biological Therapy, by Country USD Million (2023-2028)
  • Table 192. MEA Cancer Biological Therapy, by Type USD Million (2023-2028)
  • Table 193. MEA Cancer Biological Therapy, by Application USD Million (2023-2028)
  • Table 194. MEA Cancer Biological Therapy, by Cancer USD Million (2023-2028)
  • Table 195. Middle East Cancer Biological Therapy, by Type USD Million (2023-2028)
  • Table 196. Middle East Cancer Biological Therapy, by Application USD Million (2023-2028)
  • Table 197. Middle East Cancer Biological Therapy, by Cancer USD Million (2023-2028)
  • Table 198. Africa Cancer Biological Therapy, by Type USD Million (2023-2028)
  • Table 199. Africa Cancer Biological Therapy, by Application USD Million (2023-2028)
  • Table 200. Africa Cancer Biological Therapy, by Cancer USD Million (2023-2028)
  • Table 201. North America Cancer Biological Therapy, by Country USD Million (2023-2028)
  • Table 202. North America Cancer Biological Therapy, by Type USD Million (2023-2028)
  • Table 203. North America Cancer Biological Therapy, by Application USD Million (2023-2028)
  • Table 204. North America Cancer Biological Therapy, by Cancer USD Million (2023-2028)
  • Table 205. United States Cancer Biological Therapy, by Type USD Million (2023-2028)
  • Table 206. United States Cancer Biological Therapy, by Application USD Million (2023-2028)
  • Table 207. United States Cancer Biological Therapy, by Cancer USD Million (2023-2028)
  • Table 208. Canada Cancer Biological Therapy, by Type USD Million (2023-2028)
  • Table 209. Canada Cancer Biological Therapy, by Application USD Million (2023-2028)
  • Table 210. Canada Cancer Biological Therapy, by Cancer USD Million (2023-2028)
  • Table 211. Mexico Cancer Biological Therapy, by Type USD Million (2023-2028)
  • Table 212. Mexico Cancer Biological Therapy, by Application USD Million (2023-2028)
  • Table 213. Mexico Cancer Biological Therapy, by Cancer USD Million (2023-2028)
  • Table 214. Cancer Biological Therapy: by Type(USD/Units)
  • Table 215. Research Programs/Design for This Report
  • Table 216. Key Data Information from Secondary Sources
  • Table 217. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Cancer Biological Therapy: by Type USD Million (2017-2022)
  • Figure 5. Global Cancer Biological Therapy: by Application USD Million (2017-2022)
  • Figure 6. Global Cancer Biological Therapy: by Cancer USD Million (2017-2022)
  • Figure 7. South America Cancer Biological Therapy Share (%), by Country
  • Figure 8. Asia Pacific Cancer Biological Therapy Share (%), by Country
  • Figure 9. Europe Cancer Biological Therapy Share (%), by Country
  • Figure 10. MEA Cancer Biological Therapy Share (%), by Country
  • Figure 11. North America Cancer Biological Therapy Share (%), by Country
  • Figure 12. Global Cancer Biological Therapy: by Type USD/Units (2017-2022)
  • Figure 13. Global Cancer Biological Therapy share by Players 2022 (%)
  • Figure 14. Global Cancer Biological Therapy share by Players (Top 3) 2022(%)
  • Figure 15. Global Cancer Biological Therapy share by Players (Top 5) 2022(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. ELI Lilly (United States) Revenue, Net Income and Gross profit
  • Figure 18. ELI Lilly (United States) Revenue: by Geography 2022
  • Figure 19. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 20. Sanofi (France) Revenue: by Geography 2022
  • Figure 21. Merck (United States) Revenue, Net Income and Gross profit
  • Figure 22. Merck (United States) Revenue: by Geography 2022
  • Figure 23. Bayer (Germany) Revenue, Net Income and Gross profit
  • Figure 24. Bayer (Germany) Revenue: by Geography 2022
  • Figure 25. Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 26. Roche (Switzerland) Revenue: by Geography 2022
  • Figure 27. Novartis International (Switzerland) Revenue, Net Income and Gross profit
  • Figure 28. Novartis International (Switzerland) Revenue: by Geography 2022
  • Figure 29. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 30. Pfizer (United States) Revenue: by Geography 2022
  • Figure 31. Bristol-Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 32. Bristol-Myers Squibb (United States) Revenue: by Geography 2022
  • Figure 33. Seattle Genetics (United States) Revenue, Net Income and Gross profit
  • Figure 34. Seattle Genetics (United States) Revenue: by Geography 2022
  • Figure 35. Amgen (United States) Revenue, Net Income and Gross profit
  • Figure 36. Amgen (United States) Revenue: by Geography 2022
  • Figure 37. Global Cancer Biological Therapy: by Type USD Million (2023-2028)
  • Figure 38. Global Cancer Biological Therapy: by Application USD Million (2023-2028)
  • Figure 39. Global Cancer Biological Therapy: by Cancer USD Million (2023-2028)
  • Figure 40. South America Cancer Biological Therapy Share (%), by Country
  • Figure 41. Asia Pacific Cancer Biological Therapy Share (%), by Country
  • Figure 42. Europe Cancer Biological Therapy Share (%), by Country
  • Figure 43. MEA Cancer Biological Therapy Share (%), by Country
  • Figure 44. North America Cancer Biological Therapy Share (%), by Country
  • Figure 45. Global Cancer Biological Therapy: by Type USD/Units (2023-2028)
List of companies from research coverage that are profiled in the study
  • ELI Lilly (United States)
  • Sanofi (France)
  • Merck (United States)
  • Bayer (Germany)
  • Roche (Switzerland)
  • Novartis International (Switzerland)
  • Pfizer (United States)
  • Bristol-Myers Squibb (United States)
  • Seattle Genetics (United States)
  • Amgen (United States)
Additional players considered in the study are as follows:
Takeda Pharmaceuticals (Japan) , GlaxoSmithKline (United Kingdom) , Spectrum Pharmaceuticals (United States)
Select User Access Type

Key Highlights of Report


May 2023 242 Pages 67 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Cancer Biological Therapy Quantitative research analysis
Global Cancer Biological Therapy Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Historical year: 2018-2022; Base year: 2022; Forecast period: 2023 to 2028
Companies that are profiled in Global Cancer Biological Therapy Market are ELI Lilly (United States), Sanofi (France), Merck (United States), Bayer (Germany), Roche (Switzerland), Novartis International (Switzerland), Pfizer (United States), Bristol-Myers Squibb (United States), Seattle Genetics (United States) and Amgen (United States) etc.
Hospitals segment in Global market to hold robust market share owing to "Increase in incidence of cancer across the globe. There are near about ~33 million people are fighting with cancer across the globe. According to a few syndicated research, there are 70 % chances of increasing the number of cancer cases across the globe. Across the globe, people are investing in various new research to treat cancer.".
AMA Research predicts that United States Players will contribute to the maximum growth of Global Cancer Biological Therapy market throughout the forecasted period.

Know More About Global Cancer Biological Therapy Report?

Have a Query? Click Here

Other Related Reports

Ascites Comprehensive Study by Type (Exudate Ascites, Transudative Ascites), Application (Hospitals, Clinics, Ambulatory Surgical Centers, Diagnostics Centers, Others), Diagnosis (Angiography, Ultras...
$ 3650
Acute Intermittent Porphyria Comprehensive Study by Treatment (Gonadotropin-Releasing Hormone Analogues, Prophylactic Hematin Infusions, Others), Diagnosis (Blood Test, Urine Test, DNA Test, Serum Te...
$ 3450
Neurodegenerative Diseases Comprehensive Study by Application (Alzheimer's Disease, Huntington Disease, Parkinson's Disease, Amyotrophic Lateral Sclerosis), Drug Type (N-methyl-D-aspartate Receptor, ...
$ 3450
New Generation Implants Comprehensive Study by Type (Endosteal,, Subperiosteal,, Zygomatic.), Application (Orthopedic Implants, Cardiovascular Implants, Ocular Implants, Dental Implants), Raw Materia...
$ 3500
Bartter Syndrome Treatment Comprehensive Study by Type (Medication, Therapy), Application (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Genes Types (LC12A1 Gene, KCNJ1 Gene, CLCNKB Gen...
$ 3750
Nasopharyngeal Cancer Comprehensive Study by Type (Keratinizing Squamous Cell Carcinoma, Nonkeratinizing Squamous Cell Carcinoma, Undifferentiated or Poorly Differentiated), Application (Hospitals, C...
$ 3650